(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 15.92% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Transmedics Group's revenue in 2025 is $531,292,000.On average, 5 Wall Street analysts forecast TMDX's revenue for 2025 to be $20,461,270,304, with the lowest TMDX revenue forecast at $20,355,010,664, and the highest TMDX revenue forecast at $20,602,165,745. On average, 5 Wall Street analysts forecast TMDX's revenue for 2026 to be $24,599,464,528, with the lowest TMDX revenue forecast at $24,361,650,205, and the highest TMDX revenue forecast at $24,785,495,601.
In 2027, TMDX is forecast to generate $28,035,567,871 in revenue, with the lowest revenue forecast at $27,248,080,647 and the highest revenue forecast at $28,496,128,580.